Hat Trick For Xofluza As Canadian, Swiss & Australian Regulators Join Forces
Executive Summary
Xofluza is also the first non-cancer drug to be reviewed under the Australia-Canada-Singapore-Switzerland (ACSS) Consortium’s work-sharing initiative.
You may also be interested in...
International Regulators Explain Work-Sharing Scheme For Biosimilars
New guidance from the ACCESS Consortium of regulators from five countries explains how biosimilar drug sponsors can apply for an internationally-coordinated review of new products.
International Regulators Explain Work-Sharing Scheme For Biosimilars
New guidance from the ACCESS Consortium of regulators from five countries explains how biosimilar drug sponsors can apply for an internationally-coordinated review of new products.
International Regulator Consortium Eyes Real-World Data
The five-member ACCESS Consortium has outlined how it intends to build on its work-sharing experiences by applying innovative regulatory practices to the assessment of increasingly complex medicinal products.